NCT03963362Unknown1 期
Clinical Study to Evaluate Pharmacokinetics of GLA5PR Tablet According to the Renal Function
GL Pharm Tech Corporation1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2019年9月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The Cmax of Pregabalin
研究概览
简要总结
To evauate pharmacokinetics of GLA5PR tablet according to the renal function
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subject who, at the time of screening, are the age between 19 and 64 years
- •Subject who has body weight more than 50 kg (45 kg in women), and less than 80 kg
- •Subject who normal renal function of the creatinine clearance calculated by Cockcroft-Gault equation over 90 mL/min
- •Subject who the mild renal function of the creatinine clearance between 60 and 89 mL/min calculated by Cockcroft-Gault equation
- •Subject who the moderate renal patient of the creatinine clearance between 30 and 59 mL/min calculated by Cockcroft-Gault equation
- •Subject who is clinically no significant by a medical history, physical, and psychological examination
- •Subject who clinically no significant a vital sign with Investigator's judgment
- •Subject who has result of diagnostic laboratory test excluding the items described in exclusion criteria of the 13, and 14, and judged to be clinically no significant when medically by investigator
- •Subject who has consented to use a combination of effective contraceptive methods or medically appropriate contraceptive methods from the first administration of the clinical trial drug to the end of the clinical trial (when testing for final safety evaluation) and not to provide sperm or egg
- •Subject who is negative the serum and urine hCG test, and is not to pregnant and feeding
- •Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial
- •Subject who is accept to the post-study visit and to be willing to providing of collection the blood, and urine
排除标准
- •Subject who is any history of gastrointestinal disease (e.g., Crohn's disease, and others), and surgery (except for simple appendectomy or repair of a hernia), which can influence the absorption of investigational products
- •Subject who has a history of hypersensitivity or clinically significant hypersensitivity reactions to drugs or other drugs (aspirin, antibiotics, etc.) that contain components of the clinical trial drug or components of the same class (except for inactive allergic rhinitis)
- •Subject who is genetic problem such as galactose intolerance, or Lapp lactose dehydrogenase deficiency, or glucose-galactose uptake disorder
- •Subject with the exclusion criteria of 1 to 3, or a significant disease (epilepsy, etc.) and past disease that is considered difficult to participate in clinical trials according to the investigator's judgement
- •Subject who had whole blood donation within 60 days or component blood donation within 30 days before the first administration of the investigational product, or transfusion within 60 days before the first administration
- •Subject who has participated in any other clinical trials and had medication within 180 days prior to the first administration of investigational product
- •Subject who has taken any ethical-the-counter drug or has taken any over-the-counter drug within 14 days before the screening visit, except to the taken the prior-medication for the disease treatment
- •Subject who has taken any oriental medicines or any dietary supplements within 30 days, before the screening visit
- •Subject who has taken any heavy drinking within 30 days before the screening visit (>21 units/week)
- •Subject who has taken a food expected to have an effect on the clinical trial within 7 days, before the screening visit; The food of contained in caffeine (> 2 times/day) The products containing grapefruit (> 2 times/day)
- •Subject who has shown positive reaction to drugs that may be abused from a urine drug screening
- •Subject who is positive result in smoking or urine nicotine test within 30 days, before the screening visit
- •Subject who is positive result in serum test (hepatitis type B test, hepatitis type C test, Human Immunodeficiency Virus (HIV) test, and syphilis test), during the screening period
- •Subject who showed the following findings in the tests conducted during the screening period;
- •Less than the lower normal limit (LNL) in the Hb.
- •In excess of 1.5 times the upper normal limit (UNL) in the hepatic enzyme (AST and ALT), and the alkaline phosphatase values
- •In excess of 1.5 times the upper normal limit (UNL) in the total bilirubin
- •Subject who is QTc > 450 msec in ECG or a clinically significant abnormal rhythm during the screening period
- •Subject who is not eligible person for the clinical trial according to the investigator's judgment
研究组 & 干预措施
Administration of GLA5PR 75 mg as 60~89 mL/min
Experimental
Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
干预措施: GLA5PR tablet 75 mg (Drug)
Administration of GLA5PR 75 mg over 90 mL/min
Experimental
Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
干预措施: GLA5PR tablet 75 mg (Drug)
Administration of GLA5PR 150 mg as 60~89 mL/min
Experimental
Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
干预措施: GLA5PR tablet 150 mg (Drug)
Administration of GLA5PR 150 mg over 90 mL/min
Experimental
Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
干预措施: GLA5PR tablet 150 mg (Drug)
Administration of GLA5PR 75 mg as 30~59 mL/min
Experimental
Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
干预措施: GLA5PR tablet 75 mg (Drug)
结局指标
主要结局
The Cmax of Pregabalin
时间窗: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration
Cmax
The AUClast of Pregabalin
时间窗: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration
AUClast
次要结局
- CL/F of Pregabalin(Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration)
- tmax of Pregabalin(Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72 hours after administration)
- t1/2beta of Pregabalin(Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration)
- AUCinf of Pregabalin(Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration)
- Vz/F of Pregabalin(Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)Type 2 Diabetes MellitusLiver DysfunctionNCT04349696Orient Europharma Co., Ltd.16
已完成
1 期
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female SubjectsRenal FunctionNCT02634437Allergan19
已完成
1 期
A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male VolunteersHealthyNCT02327000GL Pharm Tech Corporation40
已完成
1 期
PK Study of ACHN-490 Injection in Renally Impaired SubjectsRenal InsufficiencyNCT01462136Achaogen, Inc.24
已完成
1 期
A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male SubjectsHealthyNCT02326987GL Pharm Tech Corporation30